489 related articles for article (PubMed ID: 15571424)
1. Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment.
Malaguarnera M; Pistone G; Neri S; Romano M; Brogna A; Musumeci S
BioDrugs; 2004; 18(6):407-13. PubMed ID: 15571424
[TBL] [Abstract][Full Text] [Related]
2. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
Zeuzem S; Yoshida EM; Benhamou Y; Pianko S; Bain VG; Shouval D; Flisiak R; Rehak V; Grigorescu M; Kaita K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG
Hepatology; 2008 Aug; 48(2):407-17. PubMed ID: 18666223
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Scott LJ; Perry CM
Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of interferon-alpha-ribavirin-interleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1.
Alric L; Thebault S; Peron JM; Balard P; Metivier S; Pipy B; Izopet J; Vinel JP
J Viral Hepat; 2006 Feb; 13(2):139-44. PubMed ID: 16436132
[TBL] [Abstract][Full Text] [Related]
5. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
[TBL] [Abstract][Full Text] [Related]
6. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
[TBL] [Abstract][Full Text] [Related]
7. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
J Interferon Cytokine Res; 2008 Oct; 28(10):623-9. PubMed ID: 18778199
[TBL] [Abstract][Full Text] [Related]
8. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
Maddrey WC
Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
[TBL] [Abstract][Full Text] [Related]
9. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
Oze T; Hiramatsu N; Yakushijin T; Kurokawa M; Igura T; Mochizuki K; Imanaka K; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Inui Y; Hijioka T; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Yoshida Y; Tatsumi T; Ohkawa K; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
J Viral Hepat; 2009 Aug; 16(8):578-85. PubMed ID: 19552663
[TBL] [Abstract][Full Text] [Related]
11. First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.
Reiser M; Buggisch P; Grossmann J; Koop K; Wursthorn K; Schmiegel W
Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1299-304. PubMed ID: 14624153
[TBL] [Abstract][Full Text] [Related]
12. [Applying of recombinant interleukin-1β to treat chronic hepatitis C for patients non-response to the previous antiviral therapy].
Fazylov VKh; Tkacheva SV; Manapova ÉR
Eksp Klin Gastroenterol; 2014; (10):64-9. PubMed ID: 25911934
[TBL] [Abstract][Full Text] [Related]
13. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.
Barbaro G; Di Lorenzo G; Belloni G; Ferrari L; Paiano A; Del Poggio P; Bacca D; Fruttaldo L; Mongiò F; Francavilla R; Scotto G; Grisorio B; Calleri G; Annese M; Barelli A; Rocchetto P; Rizzo G; Gualandi G; Poltronieri I; Barbarini G
Am J Med; 1999 Aug; 107(2):112-8. PubMed ID: 10460040
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.
Alfaleh FZ; Hadad Q; Khuroo MS; Aljumah A; Algamedi A; Alashgar H; Al-Ahdal MN; Mayet I; Khan MQ; Kessie G
Liver Int; 2004 Dec; 24(6):568-74. PubMed ID: 15566506
[TBL] [Abstract][Full Text] [Related]
16. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
Akhan SC; Gurel E; Sayan M
Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
Glesby MJ; Bassett R; Alston-Smith B; Fichtenbaum C; Jacobson EL; Brass C; Owens S; Sulkowski M; Race EM; Sherman KE;
J Infect Dis; 2005 Mar; 191(5):686-93. PubMed ID: 15688281
[TBL] [Abstract][Full Text] [Related]
18. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
Saracco G; Olivero A; Ciancio A; Carenzi S; Smedile A; Cariti G; Andreoni M; Orsi PG; Biglino A; Tabone M; Roffi L; Croce G; Manca A; Tappero G; Ciccone G; Rizzetto M
Hepatology; 2002 Oct; 36(4 Pt 1):959-66. PubMed ID: 12297844
[TBL] [Abstract][Full Text] [Related]
19. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
